Patents Assigned to GelTex Pharmaceuticals, Inc.
-
Publication number: 20050260236Abstract: The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 80% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.Type: ApplicationFiled: March 31, 2003Publication date: November 24, 2005Applicant: GelTex Pharmaceuticals, Inc.Inventors: Joseph Tyler, John Petersen
-
Publication number: 20040022759Abstract: A method for treating a microbial infection in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising an amino group or an ammonium group attached to the polymer backbone via an aliphatic spacer group. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.Type: ApplicationFiled: February 25, 2003Publication date: February 5, 2004Applicant: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, Thomas X. Neenan, Stephen Randall Holmes-Farley
-
Publication number: 20040019113Abstract: Disclosed are compounds which have been identified as inhibitors of phosphate transport.Type: ApplicationFiled: December 20, 2002Publication date: January 29, 2004Applicant: GelTex Pharmaceuticals, Inc.Inventors: Thomas H. Jozefiak, Cecilia M. Bastos, Andrew T. Papoulis, Stephen Randall Holmes-Farley
-
Publication number: 20040019020Abstract: Disclosed is a phosphate transport inhibiting compound represented by Structural Formula (I): 1Type: ApplicationFiled: March 19, 2003Publication date: January 29, 2004Applicant: GelTex Pharmaceuticals, Inc.Inventors: Thomas H. Jozefiak, Cecilia M. Bastos, Chad C. Huval
-
Publication number: 20040014899Abstract: The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent.Type: ApplicationFiled: October 3, 2002Publication date: January 22, 2004Applicant: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, Stephen Randall Holmes-Farley
-
Publication number: 20040009145Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.Type: ApplicationFiled: December 19, 2002Publication date: January 15, 2004Applicant: GelTex Pharmaceuticals, Inc.Inventors: Richard Fitzpatrick, Chad Cori Huval, Caroline Isabelle Bacon Kurtz, W. Harry Mandeville, Thomas X. Neenan
-
Patent number: 6646157Abstract: The preparation of a mono-cationic salt of N,N′-bis(2-hydroxybenzyl)-ethylenediamine-N,N′-diacetic acid (HBED) and HBED itself is disclosed. In particular, the invention relates to the hydrolysis of the t-butyl ester of HBED with a weak acid, such as formic acid, to form HBED, and the subsequent reaction with an equimolar amount of a base to form the mono-cationic salt.Type: GrantFiled: December 21, 2000Date of Patent: November 11, 2003Assignee: Geltex Pharmaceuticals, Inc.Inventor: James M. McKearin
-
Publication number: 20030185789Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.Type: ApplicationFiled: February 5, 2003Publication date: October 2, 2003Applicant: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, Molly Kate Boie, Venkata R. Garigapati
-
Publication number: 20030138397Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.Type: ApplicationFiled: November 14, 2002Publication date: July 24, 2003Applicant: GelTex Pharmaceuticals, Inc.Inventors: Caroline Isabelle Bacon Kurtz, Richard Fitzpatrick
-
Publication number: 20030133902Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.Type: ApplicationFiled: December 17, 2002Publication date: July 17, 2003Applicant: GelTex Pharmaceuticals, Inc.Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, George M. Whitesides
-
Patent number: 6593366Abstract: A method for treating a microbial infection in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising an amino group or an ammonium group attached to the polymer backbone via an aliphatic spacer group. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.Type: GrantFiled: February 21, 2002Date of Patent: July 15, 2003Assignee: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, III, Thomas X. Neenan, Stephen Randall Holmes-Farley
-
Patent number: 6572850Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.Type: GrantFiled: November 16, 2000Date of Patent: June 3, 2003Assignee: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, III, Molly Kate Boie, Venkata R. Garigapati
-
Patent number: 6565895Abstract: The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.Type: GrantFiled: June 8, 2001Date of Patent: May 20, 2003Assignee: GelTex Pharmaceuticals, Inc.Inventors: Philip J. Goddard, Jeffrey D. Klinger, Pradeep K. Dhal, W. Harry Mandeville, III, Richard J. Fitzpatrick, Thomas X. Neenan
-
Patent number: 6566407Abstract: A method for reducing oxalate levels in a patient that includes administering to the patient a therapeutically effective amount of non-absorbable amine polymers such as a polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.Type: GrantFiled: June 26, 2001Date of Patent: May 20, 2003Assignee: GelTex Pharmaceuticals, Inc.Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III
-
Publication number: 20030086898Abstract: A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymers characterized by a repeat unit having the formula: 1Type: ApplicationFiled: May 29, 2002Publication date: May 8, 2003Applicant: GelTex Pharmaceuticals, Inc.Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, Steven K. Burke, Dennis I. Goldberg
-
Patent number: 6558657Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.Type: GrantFiled: November 16, 2000Date of Patent: May 6, 2003Assignee: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, III, Molly Kate Boie, Venkata R. Garigapati
-
Publication number: 20030064963Abstract: Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): 1Type: ApplicationFiled: June 27, 2002Publication date: April 3, 2003Applicant: GelTex Pharmaceuticals, Inc.Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, Pradeep K. Dhal, Chad Cori Huval, Xinhua Li
-
Publication number: 20030059399Abstract: Disclosed are polymers comprising one or more phenyl boronate ester, boronamide or boronate thioester groups.Type: ApplicationFiled: June 27, 2002Publication date: March 27, 2003Applicant: GelTex Pharmaceuticals, Inc.Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, Pradeep K. Dhal, Chad Cori Huval, Xinhua Li, Steven Craig Polomoscanik
-
Publication number: 20030049226Abstract: The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: 1Type: ApplicationFiled: April 17, 2002Publication date: March 13, 2003Applicant: GelTex Pharmaceuticals, Inc. Waltham, MAInventors: Steven K. Burke, Joanne M. Donovan
-
Publication number: 20030039627Abstract: A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer, for example, an aliphatic amine polymer. In one embodiment, the polymer binds to uric acid or a precursor thereof. Examples of polymers useful in an embodiment of the invention include sevelamer hydrochloride and colesevelam.Type: ApplicationFiled: April 17, 2002Publication date: February 27, 2003Applicant: GelTex Pharmaceutical, Inc.Inventors: Stephen Randall Holmes-Farley, Steven K. Burke